PCK1 and melanoma: 3-MPA, a known inhibitor of gluconeogenesis, can inhibit PCK1 selectively, and shows a good performance in antitumor activity [11,12].However, the mechanism of PCK1 in melanoma remains unknown and regulation of metabolic reprogramming may be an Achilles’ heel of chemoresistance.